Research Analysts Offer Predictions for RNAZ FY2024 Earnings

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) – Equities researchers at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of TransCode Therapeutics in a research report issued on Wednesday, December 18th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($4.76) per share for the year, up from their prior forecast of ($60.73). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($60.73) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ Q4 2024 earnings at ($3.21) EPS, FY2025 earnings at ($4.37) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.77) EPS and FY2028 earnings at ($0.62) EPS.

TransCode Therapeutics Price Performance

RNAZ stock opened at $3.58 on Monday. TransCode Therapeutics has a one year low of $3.21 and a one year high of $264.00. The firm has a 50-day simple moving average of $380.38 and a two-hundred day simple moving average of $542.28.

Institutional Investors Weigh In On TransCode Therapeutics

An institutional investor recently raised its position in TransCode Therapeutics stock. Sheets Smith Wealth Management grew its stake in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,138 shares of the company’s stock after buying an additional 30,000 shares during the period. Sheets Smith Wealth Management owned 0.29% of TransCode Therapeutics worth $29,000 at the end of the most recent quarter.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.